Clinical Trials Browser

Phase 2 × remdesivir × 90 days × Clear all

NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Phase 2 Recruiting

Autoimmune Diseases, Respiratory Syncytial Virus Infections